{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T15:37:21Z","timestamp":1762875441919},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2012,4,24]],"date-time":"2012-04-24T00:00:00Z","timestamp":1335225600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2012,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>The financial burden of medical expenses has been increasing for cancer patients. We investigated the relationship between household income and financial burden among patients with chronic myelogenous leukaemia (CML) who have been treated with imatinib.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>A questionnaire was distributed to 1200 patients between May and August 2009. We retrospectively surveyed their household incomes, out-of-pocket medical expenses, final co-payments after refunds, and the perceived financial burden of their medical expenses in 2000, 2005 and 2008.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>A total of 577 patients completed the questionnaire. Their median age was 61\u2009years (range, 15\u201394). A financial burden was felt by 41.2\u2009% (28 of 68) of the patients treated with imatinib in 2000, 70.8\u2009% (201 of 284) in 2005, and 75.8\u2009% (400 of 528) in 2008. Overall, 182 patients (31.7\u2009%) considered its discontinuation because of the financial burden and 15 (2.6\u2009%) temporarily stopped their imatinib prescription. In 2000, 2005 and 2008, the patients\u2019 median annual household incomes were 49,615 US Dollars (USD), 38,510 USD and 36,731 USD, respectively, with an average currency exchange rate of 104 Yen\/USD in 2008. Their median annual out-of-pocket expenses were 11,548, 12,067 and 11,538 USD and their median final annual co-payments were 4,375, 4,327 and 3,558 USD, respectively. Older patients (OR\u2009=\u20090.96, 95\u2009% CI: 0.95\u20130.98, <jats:italic>p<\/jats:italic>\u2009\u226a\u20090.0001 for 1-year increments), and patients with higher household incomes (OR\u2009=\u20090.92, 95\u2009% CI: 0.85\u20130.99, <jats:italic>p<\/jats:italic>\u2009=\u20090.03 for 10,000 USD-increments) were less likely to have considered discontinuing their imatinib treatment. Conversely, patients with higher annual final co-payments (OR\u2009=\u20092.21, 95\u2009% CI: 1.28\u20134.28, <jats:italic>p<\/jats:italic>\u2009=\u20090.004 for 10,000 USD-increments) were more likely to have considered discontinuing their imatinib treatment.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>The proportion of CML patients who sensed a financial burden increased between 2000 and 2008. During this period, their annual incomes fell by 13,000 USD, although their medical expenses did not change. Financial support for patients being treated with expensive drugs remains a major problem in Japan.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/1471-2407-12-152","type":"journal-article","created":{"date-parts":[[2012,4,24]],"date-time":"2012-04-24T18:33:38Z","timestamp":1335292418000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Increased financial burden among patients with chronic myelogenous leukaemia receiving imatinib in Japan: a retrospective survey"],"prefix":"10.1186","volume":"12","author":[{"given":"Yuko","family":"Kodama","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryoko","family":"Morozumi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoko","family":"Matsumura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yukiko","family":"Kishi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoko","family":"Murashige","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuji","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Morihito","family":"Takita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobuyo","family":"Hatanaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eiji","family":"Kusumi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahiro","family":"Kami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akihiko","family":"Matsui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2012,4,24]]},"reference":[{"key":"3391_CR1","doi-asserted-by":"publisher","first-page":"3234","DOI":"10.1200\/JCO.2009.26.2758","volume":"28","author":"A Mason","year":"2010","unstructured":"Mason A, Drummond M, Ramsey S, Campbell J, Raisch D: Comparison of anticancer drug coverage decisions in the United States and United Kingdom: does the evidence support the rhetoric?. J Clin Oncol. 2010, 28: 3234-3238. 10.1200\/JCO.2009.26.2758.","journal-title":"J Clin Oncol"},{"key":"3391_CR2","doi-asserted-by":"publisher","first-page":"5830","DOI":"10.1200\/JCO.2009.22.7793","volume":"27","author":"L Mileshkin","year":"2009","unstructured":"Mileshkin L, Schofield PE, Jefford M, Agalianos E, Levine M, Herschtal A, Savulescu J, Thomson JA, Zalcberg JR: To tell or not to tell: the community wants to know about expensive anticancer drugs as a potential treatment option. J Clin Oncol. 2009, 27: 5830-5837. 10.1200\/JCO.2009.22.7793.","journal-title":"J Clin Oncol"},{"key":"3391_CR3","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1002\/art.24724","volume":"61","author":"F Wolfe","year":"2009","unstructured":"Wolfe F, Michaud K: Out-of-pocket expenses and their burden in patients with rheumatoid arthritis. Arthritis Rheum. 2009, 61: 1563-1570. 10.1002\/art.24724.","journal-title":"Arthritis Rheum"},{"key":"3391_CR4","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1016\/S0140-6736(11)60828-3","volume":"378","author":"N Ikegami","year":"2011","unstructured":"Ikegami N, Yoo BK, Hashimoto H, Matsumoto M, Ogata H, Babazono A, Watanabe R, Shibuya K, Yang BM, Reich MR, Kobayashi Y: Japanese universal health coverage:evolution, achievements, and challenges. Lancet. 2011, 378: 1106-1115. 10.1016\/S0140-6736(11)60828-3.","journal-title":"Lancet"},{"key":"3391_CR5","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1007\/s10147-010-0045-x","volume":"15","author":"T Shiroiwa","year":"2010","unstructured":"Shiroiwa T, Fukuda T, Tsutani K: Out-of-pocket payment and cost-effectiveness of XELOX and XELOX plus bevacizumab therapy: from the perspective of metastatic colorectal cancer patients in Japan. Int J Clin Oncol. 2010, 15: 256-262. 10.1007\/s10147-010-0045-x.","journal-title":"Int J Clin Oncol"},{"key":"3391_CR6","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1038\/nm0596-561","volume":"2","author":"BJ Druker","year":"1996","unstructured":"Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, Fanning S, Zimmermann J, Lydon NB: Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med. 1996, 2: 561-566. 10.1038\/nm0596-561.","journal-title":"Nat Med"},{"key":"3391_CR7","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1056\/NEJM200104053441401","volume":"344","author":"BJ Druker","year":"2001","unstructured":"Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM, Lydon NB, Kantarjian H, Capdeville R, Ohno-Jones S, Sawyers CL: Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med. 2001, 344: 1031-1037. 10.1056\/NEJM200104053441401.","journal-title":"N Engl J Med"},{"key":"3391_CR8","doi-asserted-by":"publisher","first-page":"2408","DOI":"10.1056\/NEJMoa062867","volume":"355","author":"BJ Druker","year":"2006","unstructured":"Druker BJ, Guilhot F, O\u2019Brien SG, Gathmann I, Kantarjian H, Gattermann N, Deininger MW, Silver RT, Goldman JM, Stone RM, Cervantes F, Hochhaus A, Powell BL, Gabrilove JL, Rousselot P, Reiffers J, Cornelissen JJ, Hughes T, Agis H, Fischer T, Verhoef G, Shepherd J, Saglio G, Gratwohl A, Nielsen JL, Radich JP, Simonsson B, Taylor K, Baccarani M, So C, et al: Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 2006, 355: 2408-2417. 10.1056\/NEJMoa062867.","journal-title":"N Engl J Med"},{"key":"3391_CR9","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1007\/s12185-009-0263-z","volume":"89","author":"M Sakai","year":"2009","unstructured":"Sakai M, Miyazaki Y, Matsuo E, Moriuchi Y, Hata T, Fukushima T, Imaizumi Y, Imanishi D, Taguchi J, Iwanaga M, Tsushima H, Inoue Y, Takasaki Y, Tsuchiya T, Komoda M, Ando K, Horio K, Moriwaki Y, Tominaga S, Itonaga H, Nagai K, Tsukasaki K, Tsutsumi C, Sawayama Y, Yamasaki R, Ogawa D, Kawaguchi Y, Ikeda S, Yoshida S, Onimaru Y, et al: Long-term efficacy of imatinib in a practical setting is correlated with imatinib trough concentration that is influenced by body size: a report by the Nagasaki CML Study Group. Int J Hematol. 2009, 89: 319-325. 10.1007\/s12185-009-0263-z.","journal-title":"Int J Hematol"},{"key":"3391_CR10","doi-asserted-by":"publisher","first-page":"2138","DOI":"10.1200\/JCO.2003.12.154","volume":"21","author":"EA Hahn","year":"2003","unstructured":"Hahn EA, Glendenning GA, Sorensen MV, Hudgens SA, Druker BJ, Guilhot F, Larson RA, O\u2019Brien SG, Dobrez DG, Hensley ML, Cella D, IRIS Investigators: Quality of life in patients with newly diagnosed chronic phase chronic myeloid leukemia on imatinib versus interferon alfa plus low-dose cytarabine: results from the IRIS Study. J Clin Oncol. 2003, 21: 2138-2146. 10.1200\/JCO.2003.12.154.","journal-title":"J Clin Oncol"},{"key":"3391_CR11","volume-title":"Red Book: Pharmacy\u2019s Fundamental Reference","author":"Thompson Healthcare","year":"2008","unstructured":"Thompson Healthcare: Red Book: Pharmacy\u2019s Fundamental Reference. 2008, Montvale, NJ: Thompson Healthcare"},{"key":"3391_CR12","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1007\/s00520-008-0549-3","volume":"17","author":"MI Bennett","year":"2009","unstructured":"Bennett MI, Closs SJ, Chatwin J: Cancer pain management at home (I): do older patients experience less effective management than younger patients?. Support Care Cancer. 2009, 17: 787-792. 10.1007\/s00520-008-0549-3.","journal-title":"Support Care Cancer"},{"key":"3391_CR13","volume-title":"Annual report on the family income and expenditure survey","author":"Ministry of Internal Affairs and Communications, Government of Japan","year":"2008","unstructured":"Ministry of Internal Affairs and Communications, Government of Japan: Annual report on the family income and expenditure survey. 2008, [http:\/\/www.stat.go.jp\/english\/data\/sousetai\/es08.htm]"},{"key":"3391_CR14","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1056\/NEJMc1004656","volume":"363","author":"RK Kelley","year":"2010","unstructured":"Kelley RK, Venook AP: Nonadherence to imatinib during an economic downturn. N Engl J Med. 2010, 363: 596-598. 10.1056\/NEJMc1004656.","journal-title":"N Engl J Med"},{"key":"3391_CR15","doi-asserted-by":"publisher","first-page":"481","DOI":"10.2165\/00019053-200725060-00004","volume":"25","author":"T Darkow","year":"2007","unstructured":"Darkow T, Henk HJ, Thomas SK, Feng W, Baladi JF, Goldberg GA, Hatfield A, Cortes J: Treatment interruptions and non-adherence with imatinib and associated healthcare costs: a retrospective analysis among managed care patients with chronic myelogenous leukaemia. Pharmacoeconomics. 2007, 25: 481-496. 10.2165\/00019053-200725060-00004.","journal-title":"Pharmacoeconomics"},{"key":"3391_CR16","volume-title":"The 2009 HHS Poverty Guidelines","author":"U.S. Department of Health and Human Services","year":"2009","unstructured":"U.S. Department of Health and Human Services: The 2009 HHS Poverty Guidelines. 2009, [http:\/\/aspe.hhs.gov\/poverty\/09poverty.shtml]"},{"key":"3391_CR17","volume-title":"Summary Report of Comprehensive Survey of Living Conditions","author":"Ministry of Health, Labour and Welfare, Government of Japan","year":"2009","unstructured":"Ministry of Health, Labour and Welfare, Government of Japan: Summary Report of Comprehensive Survey of Living Conditions. 2009, [http:\/\/www.mhlw.go.jp\/english\/database\/db-hss\/dl\/report_gaikyo_2009.pdf]"},{"key":"3391_CR18","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.critrevonc.2010.01.004","volume":"77","author":"A Mehnert","year":"2011","unstructured":"Mehnert A: Employment and work-related issues in cancer survivors. Crit Rev Oncol Hematol. 2011, 77: 109-130. 10.1016\/j.critrevonc.2010.01.004.","journal-title":"Crit Rev Oncol Hematol"},{"key":"3391_CR19","unstructured":"Pharmaceutical Medical Devices Agency of Japan: Glivec Tablets (in Japanese). [http:\/\/www.info.pmda.go.jp]"},{"key":"3391_CR20","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1007\/s12185-008-0230-0","volume":"89","author":"WY Au","year":"2009","unstructured":"Au WY, Caguioa PB, Chuah C, Hsu SC, Jootar S, Kim DW, Kweon IY, O\u2019Neil WM, Saikia TK, Wang J: Chronic myeloid leukemia in Asia. Int J Hematol. 2009, 89: 14-23. 10.1007\/s12185-008-0230-0.","journal-title":"Int J Hematol"},{"key":"3391_CR21","doi-asserted-by":"publisher","first-page":"6041","DOI":"10.1200\/JCO.2009.25.0779","volume":"27","author":"M Baccarani","year":"2009","unstructured":"Baccarani M, Cortes J, Pane F, Niederwieser D, Saglio G, Apperley J, Cervantes F, Deininger M, Gratwohl A, Guilhot F, Hochhaus A, Horowitz M, Hughes T, Kantarjian H, Larson R, Radich J, Simonsson B, Silver RT, Goldman J, Hehlmann R: European LeukemiaNet. Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol. 2009, 27: 6041-6051. 10.1200\/JCO.2009.25.0779.","journal-title":"J Clin Oncol"},{"key":"3391_CR22","doi-asserted-by":"publisher","first-page":"2251","DOI":"10.1056\/NEJMoa0912614","volume":"362","author":"G Saglio","year":"2010","unstructured":"Saglio G, Kim DW, Issaragrisil S, le Coutre P, Etienne G, Lobo C, Pasquini R, Clark RE, Hochhaus A, Hughes TP, Gallagher N, Hoenekopp A, Dong M, Haque A, Larson RA, Kantarjian HM, ENESTnd Investigators: Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med. 2010, 362: 2251-2259. 10.1056\/NEJMoa0912614.","journal-title":"N Engl J Med"},{"key":"3391_CR23","doi-asserted-by":"publisher","first-page":"2260","DOI":"10.1056\/NEJMoa1002315","volume":"362","author":"H Kantarjian","year":"2010","unstructured":"Kantarjian H, Shah NP, Hochhaus A, Cortes J, Shah S, Ayala M, Moiraghi B, Shen Z, Mayer J, Pasquini R, Nakamae H, Huguet F, Boqu\u00e9 C, Chuah C, Bleickardt E, Bradley-Garelik MB, Zhu C, Szatrowski T, Shapiro D, Baccarani M: Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2010, 362: 2260-2270. 10.1056\/NEJMoa1002315.","journal-title":"N Engl J Med"},{"key":"3391_CR24","unstructured":"Ministry of Health, Labour and Welfare: Various information of medical fee. [http:\/\/www.iryohoken.go.jp\/shinryohoshu\/searchMenu\/doSearchInputYp]"},{"key":"3391_CR25","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1007\/s12185-009-0315-4","volume":"89","author":"T Kawaguchi","year":"2009","unstructured":"Kawaguchi T, Hamada A, Hirayama C, Nakashima R, Nambu T, Yamakawa Y, Watanabe H, Horikawa K, Mitsuya H, Saito H: Relationship between an effective dose of imatinib, body surface area, and trough drug levels in patients with chronic myeloid leukemia. Int J Hematol. 2009, 89: 642-648. 10.1007\/s12185-009-0315-4.","journal-title":"Int J Hematol"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2407-12-152.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1471-2407-12-152\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2407-12-152","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2407-12-152.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,2]],"date-time":"2021-09-02T20:33:00Z","timestamp":1630614780000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/1471-2407-12-152"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,4,24]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,12]]}},"alternative-id":["3391"],"URL":"https:\/\/doi.org\/10.1186\/1471-2407-12-152","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,4,24]]},"assertion":[{"value":"2 December 2011","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 April 2012","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 April 2012","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"152"}}